Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05254327 · ClinicalTrials.gov registry record · Phase 2
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
A Phase 2 study of Rectal Cancer, sponsored by University of Nebraska.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 3
- Study locations
NCT05254327 is a Phase 2 study of Rectal Cancer that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 118 participants, below the 3,165-participant average among 70 other Rectal Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05254327, a Phase 2 study of Rectal Cancer, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 3
- Study locations
Study Summary
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
Conditions Studied
Interventions
- DRUG BMX-001
Study Locations (3)
Kentucky
- Markey Cancer Center - Lexington
Nebraska
- University of Nebraska Medical Center - Omaha
Texas
- UT Health San Antonio MD Anderson Cancer Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05254327
The ClinicalTrials.gov registry entry for NCT05254327 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,165-participant average among 70 other Rectal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which BMX-001 is the first listed.
NCT05254327 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kentucky, Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT05254327 about?
NCT05254327 is a clinical study titled "Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001". In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
What is the current status of trial NCT05254327?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2022-08-15. Estimated completion is 2029-06.
What conditions does trial NCT05254327 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT05254327?
The interventions under investigation include: BMX-001 (DRUG).
Who is sponsoring clinical trial NCT05254327?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05254327 being conducted?
This trial has 3 study locations across Kentucky, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.